Seamless Therapeutics

News

Black and white image of the side of a baby's face, focused on its ear

Lilly allies with gene-editing firm Seamless on hearing loss

Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.

News

FDA approves higher Wegovy dose via 4th priority voucher

The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks